Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Gebruik van een digitale psychotherapeutische app om de symptoomlast bij dermatologische patiënten te verminderen

23 september 2026 bijgewerkt door: National University Hospital, Singapore

Ontwikkeling en testen van een digitaal psychologisch hulpmiddel om de symptoomlast bij dermatologische patiënten te verbeteren

Skin diseases, despite low mortality, significantly impair quality of life. This randomised controlled trial evaluates the efficacy of a digital toolkit comprising psychotherapeutic strategies in reducing QoL burden in patients with chronic inflammatory skin conditions. This toolkit is hosted on a mobile application and will be used by study participants randomised to the intervention arm over the 32 week study period.

Studie Overzicht

Gedetailleerde beschrijving

Chronic inflammatory skin diseases, despite low mortality, significantly impair quality of life. Up to 80% of dermatological patients experience severe itch and poor sleep, and related such mental health challenges as anxiety and depression. The relationship between skin diseases and mental health highlights the challenges that doctors face in treating these conditions. Existing psychotherapeutics such as Mindfulness training, Cognitive Behavioural Therapy, and Acceptance and Commitment Therapy are widely used and effective in the treatment of mental health illness. However, there is limited evidence on the application of such interventions in dermatology and most mental health apps lack robust clinical evaluation. We report the design of a randomised controlled trial to evaluate the efficacy and implementation of a mobile app containing dermatology-specified psychotherapeutic strategies in reducing QoL burden.

Studietype

Ingrijpend

Inschrijving (Geschat)

690

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

16 jaar en ouder (Kind, Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Patients with psoriasis, eczema or chronic urticaria diagnosed by a dermatologist
  • Aged 16 or older
  • Peak pruritus intensity of 4 or more on a 11-point numerical rating scale (0-10, with 10 representing worst itch)
  • Able to engage with a mobile application in the English language

Exclusion Criteria:

  • Patients with active psychiatric symptoms (e.g. active suicidal ideation, psychosis, delusions)

  • Patients with unstable psychiatric condition, characterized by

    o Hospital inpatient admission for a psychiatric condition or initiation of a psychotropic medication in the prior 3 months

  • Patients with unstable dermatological condition, characterized by

    • Recent flare of the skin condition within the last 2 weeks, including diagnosis of a flare by a doctor, use of systemic steroids, oral antibiotics, wet wrap rescue therapy, oral antivirals, or increase in frequency of phototherapy or dose of systemic medications for the dermatological condition within the last 2 weeks OR

    • Any of the following within 3 months

      • inpatient admission for a dermatological condition
      • Initiation of phototherapy
      • Initiation of systemic therapy (conventional immunosuppressive agent, biologics, JAK inhibitors) within the last 3 months.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Ondersteunende zorg
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Verdrievoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Intervention Arm

This fully automated and self-administered intervention will be delivered via a Health Insurance Portability and Accountability Act (HIPAA) compliant mobile app developed in collaboration with Intellect Inc., a Singapore-based mobile health company with broad reach and prior research collaborations in the Asia Pacific region. A detailed discussion focusing on the engineering of the application including the user interface, data acquisition and curation technology, security and privacy assurance is available from the authors.

Mobile app comprising various psychobehavioural tools to educate, enhance self-efficacy and coping and promote wellness in dermatological patients.

Andere namen:
  • applicatie voor de mobiele telefoon
Actieve vergelijker: Control

Participants in the active control group will download use the Healthy365 app, a mobile health application managed by the Singapore government's Health Promotion Board. The Healthy365 app offers a variety of useful general health-related content which are not specific to skin disease. These include personalized health tracking, participation in fitness challenges, access to nutritional guidance, and personalized lifestyle recommendations.

Mobile application by the Health Promotion Board (HPB) Singapore which aims to encourage users to adopt a healthier lifestyle.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Skin-specific quality of life impairment
Tijdsspanne: baseline, week 8

Dermatology Life Quality Index (DLQI). Minimum Score: 0 (no impact on quality of life). Maximum Score: 30 (extremely large impact on quality of life).

baseline, week 8

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Physician assessed body surface area affected
Tijdsspanne: baseline, week 8 and 16

Range from 0% (no affected area) to 100% (complete involvement)

baseline, week 8 and 16
Investigator/physician global assessment
Tijdsspanne: baseline, week 8, week 16

0 to 5 point numerical rating scale, with a higher value signalling greater severity

baseline, week 8, week 16
Eczema severity
Tijdsspanne: baseline, week 8, week 16

Eczema Area and Severity Index. Scoring system used to assess the severity of atopic dermatitis. Score ranges from 0 to 72 with higher score indicating worse severity.

baseline, week 8, week 16
Psoriasis Severity
Tijdsspanne: baseline, week 8, week 16

Psoriasis Area and Severity Index. Severity assessment for patients with psoriasis. Score ranges from 0-72 with higher scoring indicating more severe disease.

baseline, week 8, week 16
Chronic urticaria severity
Tijdsspanne: baseline, week 8, week 16

Urticaria Activity Score-7 (UAS7). Assess severity for patients with chronic urticaria. Score ranges from 0-6.

baseline, week 8, week 16
Composite measure of scratching
Tijdsspanne: baseline, week 8, week 16

Global severity and body surface area affected of various scratching measures e.g excoriation, lichenification, prurigo

baseline, week 8, week 16
Itch
Tijdsspanne: baseline, weeks 4, 8, 12, 16, 24, 32

0-10 numerical rating scale, with higher scores signalling greater itch

baseline, weeks 4, 8, 12, 16, 24, 32
Skin pain
Tijdsspanne: baseline, week 4, week 8, week 12, week 16, week 24, week 32

0-10 numerical rating scale, greater scores signalling greater pain

baseline, week 4, week 8, week 12, week 16, week 24, week 32
Sleep disturbance
Tijdsspanne: baseline, weeks 4, 8, 12, 16, 24, 32

0-10 numerical rating scale, with higher scores signalling greater sleep disturbance

baseline, weeks 4, 8, 12, 16, 24, 32
Depression
Tijdsspanne: baseline, week 8, week 16, week 24 and 32

PROMIS (Patient-Reported Outcomes Measurement Information System) Depression 8b. The raw score range for the PROMIS Depression 8b ranges from 8 to 40 with higher scores indicating greater depressive symptoms. The raw score is then converted to a T-score using a standardized conversion table. The T scores have a mean of 50 and standard deviation (SD) of 10, a higher value signals greater depressive symptoms.

baseline, week 8, week 16, week 24 and 32
Anxiety
Tijdsspanne: baseline, weeks 8, 16, 24 and 32

PROMIS (Patient-Reported Outcomes Measurement Information System) Anxiety 7a. The raw score range from 7-35 with higher scores indicating greater anxiety symptoms. The raw score is then converted to a T-score using a standardized conversion table. The T scores have a mean of 50 and standard deviation (SD) of 10, a higher value signals greater depressive symptoms.

baseline, weeks 8, 16, 24 and 32
Number of patients requiring treatment escalation
Tijdsspanne: baseline, week 8, 16 and 32

Number of patients requiring treatment escalation, defined as any of the following

- Initiation or escalation of systemic treatments; inclusive of conventional immunosuppressants, biologics, systemic steroids

baseline, week 8, 16 and 32
Work productivity and activity impairment
Tijdsspanne: baseline and week 16

Modified Work Productivity and Activity Impairment Questionnaire plus Classroom Impairment Questions: SHP, Version 2 (WPAI+CIQ:SHP, V 2). Assesses the impact of health problems on a person's ability to work and perform regular daily activities. Scores are multiplied by 100 to express in percentages with higher scorings indicating greater impairment and less productivity.

Two additional questions assessing time spent on problems associated with skin condition and employment status, respectively.

baseline and week 16
EQ-5D-5L
Tijdsspanne: baseline, week 32

EuroQol Group EQ-5D is a measure of health state/health utility. EQ-5D-5L index scores range from -0.59 to 1, where 1 is the best possible health state

baseline, week 32
Skin-specific quality of life impairment
Tijdsspanne: week 4, week 12, week 16, week 24, week 32

Dermatology Life Quality Index (DLQI). Minimum Score: 0 (no impact on quality of life). Maximum Score: 30 (large impact on quality of life).

week 4, week 12, week 16, week 24, week 32
Implementability - App Engagement Scale
Tijdsspanne: week 32

App Engagement Scale. 7 questions graded on a likert scale. Items are summed, with scores ranging from 7 to 35, with a higher score indicating greater engagement.

week 32
Implementability - Frequency of app usage
Tijdsspanne: week 8, week 32

Frequency of using the mobile app, ranging from never to everyday

week 8, week 32
Implementability - Duration of app usage
Tijdsspanne: week 8, week 32

Average duration of app use each time, ranging from less than 2 minutes to more than 40 minutes.

week 8, week 32
Implementability - Willingness to pay
Tijdsspanne: week 32

Single bounded willingness to pay, 'How much would you maximally be willing to pay/month to continue using this mobile app?' with responses ranging from 'I would not use it even if free' to 'I would pay $41 or more /month'

week 32
Implementability - Barriers and facilitators of use
Tijdsspanne: Post 32 weeks after participant's study completion

Qualitative interviews with thematic analysis to determine barriers and facilitators of use and long term sustainability

Post 32 weeks after participant's study completion
Implementability - Percentage completed learning paths/ modules
Tijdsspanne: baseline to week 32

Passively collected in mobile app's logs.

baseline to week 32
Implementability - Appropriate responses and engagement to tracking exercises and open ended questions in the app
Tijdsspanne: Baseline to week 32

Passive collected in mobile app's logs.

Baseline to week 32
Implementability - Collective server statistics
Tijdsspanne: baseline to week 32

Mobile app's collective server access statistics is tracked to determine which pages have the lowest and highest traffic and to analyse 'helpfulness' ratings of each module.

baseline to week 32
Implementability - Likely frequency of app use after study
Tijdsspanne: week 32

Likely frequency of app usage after the study, ranging from never to everyday.

week 32
Implementability - Likes and dislikes
Tijdsspanne: week 32

Two free-text questions collecting qualitative feedback on participants' likes and dislikes about the app, respectively.

week 32
Implementability - Suggestions and feedback
Tijdsspanne: week 32

Free-text question collecting suggestions and feedback to improve the mobile app.

week 32
Physician assessed global disease severity
Tijdsspanne: baseline, week 8, week 16

Assesses patient's overall, emotional, functional, and physical severity, and physician's perception of how the patient graded overall severity. Range from 0 to 10, with higher value signalling greater severity.

baseline, week 8, week 16
Physician assessed clinical global change
Tijdsspanne: week 8, week 16

Clinician-assessed change in patient's overall status since the start of the study. Ranges from very much improved to very much worse.

week 8, week 16
Patient's disease severity grading
Tijdsspanne: baseline, week 4, week 8, week 12, week 16, week 24, week 32

A question assessing patient's overall global assessment of disease severity, ranging from 0 to 10, with higher scores indicating higher severity.

baseline, week 4, week 8, week 12, week 16, week 24, week 32
Patient Global Impression of Severity
Tijdsspanne: baseline, week 4, week 8, week 12, week 16, week 24, week 32

Patient reported global severity rating, ranging from none to very severe.

baseline, week 4, week 8, week 12, week 16, week 24, week 32
Patient Global Impression of Change
Tijdsspanne: week 4, week 8, week 12, week 16, week 24, week 32

Patient reported change in overall status from the start of the study, ranging form very much improved to very much worse.

week 4, week 8, week 12, week 16, week 24, week 32

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Type D personality
Tijdsspanne: baseline and week 16

DS-14, measure of type D personality. The negative affect and social inhibition scales are scored from 0-28 with a higher score representing greater trait. A cutoff of 10 on each scale is used to classify type D personality.

baseline and week 16
Itch characteristic
Tijdsspanne: 0, week 8

5D Pruritus scale ranges from 5 to 25, where 5 indicates no pruritus and 25 indicates the most severe pruritus.

0, week 8
Scratching behavior
Tijdsspanne: baseline, week 8, week 16, week 24, week 32

PROMIS Itch Questionnaire Scratching Behaviour 5a. Score ranges fro 0-25 with higher score indicating greater scratching behaviours. Scores are standardized with 50 representing the mean.

baseline, week 8, week 16, week 24, week 32
Acceptance of health condition
Tijdsspanne: baseline, week 8, week 16, 32

Acceptance of Chronic Health Conditions Scale. Scores range from 8 to 40. Higher scores indicate greater acceptance of the chronic health condition.

baseline, week 8, week 16, 32
Revised illness perception questionnaire
Tijdsspanne: baseline, week 8, week 16, 32

Assessment of how individuals perceive their illness including cognitive and emotional representations of illness across several dimensions. Each dimension is scored separately and expressed as a percentage (0-100%), with higher scores indicating more strongly held beliefs.

baseline, week 8, week 16, 32
Resilience
Tijdsspanne: baseline, week 8, week 16, 24, 32

Brief Resilience Scale. The total score on the Brief Resilience Scale (BRS) ranges from 6 to 30. This scale measures an individual's ability to bounce back from stress and adversity. A higher score indicates greater resilience, while a lower score suggests lower resilience.

baseline, week 8, week 16, 24, 32
Self Efficacy in managing emotions
Tijdsspanne: baseline, week 8, 32

PROMIS self-efficacy in managing emotions 4a. Score ranges from 4 to 20 which are standardized and expressed as a percentage from 0-100%, with higher score indicating greater self efficacy.

baseline, week 8, 32
Mindfulness
Tijdsspanne: baseline, week 8, 32

2 questions from the Cognitive and Affective Mindfulness Scale- Revised (CAMS-R). Score ranges from 0-6 with higher score indicating more mindfulness.

baseline, week 8, 32
Self stigmatization
Tijdsspanne: baseline, week 8, week 16, 32

Weight bias internalization scale, modified for skin conditions. The score ranges from 11 to 77. Higher scores indicate greater internalization of bias/negative perception towards self.

baseline, week 8, week 16, 32
Social Comparison
Tijdsspanne: baseline, week 8, week 16, 32

The DermSC scale comprises 3 questions, testing the general tendency for social comparison, downward negative comparison and upward negative comparison. The scores of each question (1-5 points) are tabulated (range 3-15) with a higher score indicating a greater degree of social comparison.

baseline, week 8, week 16, 32
Well being
Tijdsspanne: baseline, week 8, week 16, 24, 32

World Health Organisation-Five Well-Being Index (WHO-5) ranges from 0-25 which is converted to an index score 0-100 with 0 representing the worst imaginable well-being and 100 representing the best imaginable well-being.

baseline, week 8, week 16, 24, 32
Adherence
Tijdsspanne: baseline, week 8, week 16, 32

Self-reported treatment adherence, represented as a percentage from 0-100% where higher scores indicate greater adherence.

baseline, week 8, week 16, 32
Self-efficacy for managing social interactions
Tijdsspanne: baseline, week 8, week 32

2 questions from PROMIS Self-Efficacy for Managing Chronic Conditions - Managing Social Interactions. It assesses confidence in social activities and help seeking, ranging from I am not at confident to I am very confident.

baseline, week 8, week 32

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Ellie Choi, MBBS, National University Hospital, Singapore

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

23 februari 2026

Primaire voltooiing (Geschat)

1 december 2028

Studie voltooiing (Geschat)

1 juli 2029

Studieregistratiedata

Eerst ingediend

10 oktober 2024

Eerst ingediend dat voldeed aan de QC-criteria

20 november 2024

Eerst geplaatst (Werkelijk)

22 november 2024

Updates van studierecords

Laatste update geplaatst (Werkelijk)

28 september 2026

Laatste update ingediend die voldeed aan QC-criteria

23 september 2026

Laatst geverifieerd

1 oktober 2025

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

IPD shared includes de-identified demographics, disease outcomes and measures.

IPD-tijdsbestek voor delen

IPD and supporting information will be available from the time of publication and for four years thereafter.

IPD-toegangscriteria voor delen

IPD and supporting information will be available from the study team on a case-by-case basis upon request.

IPD delen Ondersteunend informatietype

  • LEERPROTOCOOL
  • ICF
  • ANALYTIC_CODE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren